Intelligence Feed event · Credit · 2026-09-07

    Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt

    Question

    Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt

    Direct answer

    Teva Pharmaceutical has commenced a public offering of senior notes denominated in US dollars and euros via special purpose financing vehicles. The company plans to use net proceeds to redeem its outstanding 6.750% notes due 2028 as well as its 7.875% and 7.375% sustainability-linked notes due 2029. The debt liability management transaction aims to push out intermediate maturities and lower credit spread expenses ahead of broader rate adjustments.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt”, revision 1, evidence through 2026-09-07. https://marketontology.com/market-events/2026-09-07/teva-launches-eur-and-usd-senior-notes-offering-to-redeem-2028-2029-debt-ccbfb6

    CREDIT
    Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt
    Teva Pharmaceutical has commenced a public offering of senior notes denominated in US dollars and euros via special purpose financing vehicles. The company plans to use net proceeds to redeem its outstanding 6.750% notes due 2028 as well as its 7.875% and 7.375% sustainability-linked notes due 2029. The debt liability management transaction aims to push out intermediate maturities and lower credit spread expenses ahead of broader rate adjustments.
    TEVA
    Impact
    67
    SEP 7
    SIG
    90%
    TEVA
    Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt
    Teva Pharmaceutical has commenced a public offering of senior notes denominated in US dollars and euros via special purpose financing vehicles. The company plans to use net proceeds to redeem its outstanding 6.750% notes due 2028 as well as its 7.875% and 7.375% sustainability-linked notes due 2029. The debt liability management transaction aims to push out intermediate maturities and lower credit spread expenses ahead of broader rate adjustments.
    → Refinancing high-coupon 6.750% to 7.875% debt through new dual-currency senior notes extends Teva's maturity profile and reduces forward interest expense obligations.
    Impact
    Teva Pharmaceutical has commenced a public offering of senior notes denominated in US dollars and euros via special purpose financing vehicles. The company plans to use net proceeds to redeem its outstanding 6.750% notes due 2028 as well as its 7.875% and 7.375% sustainability-linked notes due 2029. The debt liability management transaction aims to push out intermediate maturities and lower credit spread expenses ahead of broader rate adjustments.
    Affected
    TEVA
    Transmission
    Refinancing high-coupon 6.750% to 7.875% debt through new dual-currency senior notes extends Teva's maturity profile and reduces forward interest expense obligations.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAdebt maturity extension and interest expense reductionUp1-4wTeva launched notes offering to redeem 6.750% 2028 notes and 7.875%/7.375% 2029 SLNs.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month